Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity

被引:10
|
作者
van Tilburg, Cornelis M. [1 ]
Sanders, Elisabeth A. M. [2 ]
Nibbelke, Elisabeth E. [1 ]
Pieters, Rob [3 ,6 ]
Revesz, Tom [4 ]
Westers, Paul [5 ]
Wolfs, Tom F. W. [2 ]
Bierings, Marc B. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Paediat Haematol Oncol, NL-3508 AB Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Paediat Immunol & Infect Dis, NL-3508 AB Utrecht, Netherlands
[3] Dutch Childhood Oncol Grp, The Hague, Netherlands
[4] SA Pathol Womens & Childrens Hosp, Haematol Oncol Dept, Adelaide, SA, Australia
[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[6] Erasmus MC Sophia Childrens Hosp, Dept Paediat Oncol Haematol, Rotterdam, Netherlands
关键词
acute lymphoblastic leukaemia; infection; chemotherapy; child; toxicity; MINIMAL RESIDUAL DISEASE; AIEOP-BFM; CHILDREN; CANCER; THERAPY;
D O I
10.1111/j.1365-2141.2010.08463.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Reducing infectious morbidity is an important goal to improve childhood acute lymphoblastic leukaemia (ALL) survival. To explore the impact of chemotherapy reduction on infectious morbidity, we compared outpatient and inpatient infectious morbidity of reduced versus intensive (conventional) chemotherapy. One hundred and seventy-one children newly diagnosed with ALL between 2004 and 2007 and treated according to the Dutch Childhood Oncology Group ALL 10 protocol were prospectively followed during the 2-year treatment course. Stratified by minimal residual disease, 54 patients received reduced (standard risk; SR) and 117 patients received intensive (medium risk; MR) intensification/maintenance treatment. SR outpatients had a median of 1 febrile episode versus 4 in MR outpatients (P = 0 center dot 002). SR patients had fewer hospitalizations for fever. They were admitted a median of 0 times, with a median of 0 days of hospitalization, median 0 days of fever, median 0 times chemotherapy interruption and median 0 times intravenous antibiotics. MR patients were admitted for fever median 2 times (P < 0 center dot 001) with 10 days of hospitalization (P < 0 center dot 001), 2 days of fever (P < 0 center dot 001), one chemotherapy interruption (P < 0 center dot 001) and two intravenous antibiotics administration (P < 0 center dot 001). These data indicate that reduced intensification/maintenance compared to conventional intensive intensification/maintenance chemotherapy for good risk childhood ALL resulted in major decrease of infectious morbidity.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 50 条
  • [41] Consanguinity and childhood acute lymphoblastic leukaemia: a case-control study
    Kakaje, Ameer
    Alhalabi, Mohammad Marwan
    Ghareeb, Ayham
    Karam, Bahjat
    Mansour, Bassam
    Zahra, Bayan
    Hamdan, Othman
    EGYPTIAN PEDIATRIC ASSOCIATION GAZETTE, 2022, 70 (01)
  • [42] Childcare attendance and risk of childhood acute lymphoblastic leukaemia: A register study based on the Danish childcare database
    Soegaard, Signe Holst
    Rostgaard, Klaus
    Kamper-Jorgensen, Mads
    Schmiegelow, Kjeld
    Hjalgrim, Henrik
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (09) : 1817 - 1826
  • [43] Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy
    Kager, L.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 (02) : 65 - 70
  • [44] Physical activity in survivors of childhood acute lymphoblastic leukaemia
    Heath, John A.
    Ramzy, John M.
    Donath, Susan M.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2010, 46 (04) : 149 - 153
  • [45] Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia
    Diamanti, Paraskevi
    Cox, Charlotte V.
    Moppett, John P.
    Blair, Allison
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 147 - 149
  • [46] Efficacy and toxicity of high-risk therapy of the Dutch Childhood Oncology Group in childhood acute lymphoblastic leukemia
    van Binsbergen, Annelien L.
    de Haas, Valerie
    van der Velden, Vincent H. J.
    De Groot-Kruseman, Hester A.
    Fiocco, Marta F.
    Pieters, Rob
    PEDIATRIC BLOOD & CANCER, 2022, 69 (02)
  • [47] Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia
    Campana, D
    Coustan-Smith, E
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 1 - 19
  • [48] Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion
    Baruchel, Andre
    Brown, Patrick
    Rizzari, Carmelo
    Silverman, Lewis
    van der Sluis, Inge
    Wolthers, Benjamin Ole
    Schmiegelow, Kjeld
    ESMO OPEN, 2020, 5 (05)
  • [49] Impact of polymorphisms in apoptosis-related genes on the outcome of childhood acute lymphoblastic leukaemia
    Cabezas, Maria
    Camos, Mireia
    Rives, Susana
    Garcia-Orad, Africa
    Lopez-Lopez, Elixabet
    Dapena, Josep L.
    Caballin, Maria R.
    Armengol, Gemma
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) : 159 - 162
  • [50] Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy
    Leo Kager
    memo - Magazine of European Medical Oncology, 2009, 2 (2) : 65 - 70